Mdivi-1: Selective DRP1 Inhibitor for Mitochondrial Dynamics Research

Executive Summary: Mdivi-1 is a cell-permeable, selective inhibitor of the mitochondrial fission GTPase DRP1, validated in both in vitro and in vivo models to attenuate mitochondrial fragmentation and apoptosis. In chronic intermittent hypoxia (CIH), Mdivi-1 reduces apoptotic markers and restores mitochondrial function (ScienceDirect, 2026). The compound is insoluble in water and ethanol but dissolves in DMSO at ≥17.65 mg/mL (APExBIO product page). Typical laboratory concentrations are 50 μM for cell assays and 50 mg/kg for in vivo injections. APExBIO provides Mdivi-1 (SKU A4472) as a solid, supporting robust, reproducible mitochondrial dynamics research.

Biological Rationale

Mitochondria are central to cellular energy metabolism and intrinsic apoptosis regulation. Mitochondrial fission, controlled by the dynamin-related protein 1 (DRP1), is essential for quality control but excessive fission contributes to cellular injury in stress models. In chronic intermittent hypoxia (CIH), a pathological feature of obstructive sleep apnea (OSA), upregulation of mitochondrial fission and apoptosis markers is observed, leading to tissue damage and neurocognitive dysfunction (ScienceDirect, 2026). Targeting DRP1 with selective inhibitors like Mdivi-1 allows for precise modulation of mitochondrial morphology and offers a pathway to dissect the molecular mechanisms underlying apoptosis and organ injury. Recent research also implicates the gut microbiota–mitochondria axis in regulating apoptosis in CIH, with Mdivi-1 showing potential to restore metabolic and microbial homeostasis in affected tissues.

Mechanism of Action of Mdivi-1

Mdivi-1 acts as a selective inhibitor of DRP1, interfering with its GTPase activity. This action prevents DRP1 oligomerization and assembly at the mitochondrial outer membrane, blocking mitochondrial division (APExBIO product page). In both yeast and mammalian cells, Mdivi-1 treatment attenuates mitochondrial fragmentation. Mechanistically, Mdivi-1 reduces Bid-activated Bax/Bak-dependent cytochrome c release, a critical step in mitochondrial outer membrane permeabilization and apoptosis induction. This leads to decreased activation of downstream apoptotic markers such as caspase-3 and reduced annexin V staining in cell-based assays. Notably, Mdivi-1 does not alter total DRP1 protein levels, indicating a selective effect on DRP1 activity rather than expression.

Evidence & Benchmarks

• In a CIH mouse model, Mdivi-1 reduced BAX and caspase-3 expression while increasing Bcl-2, indicating suppressed apoptosis (ScienceDirect).
• Mdivi-1 restored mitochondrial morphology and function disrupted by CIH, as measured by electron microscopy and respiratory assays (ScienceDirect).
• CCCP, a mitochondrial uncoupler, exacerbated CIH-induced mitochondrial damage, but Mdivi-1 reversed these effects, demonstrating target specificity (ScienceDirect).
• Mdivi-1 partially restored gut microbiota composition and fatty acid metabolism altered by CIH, suggesting systemic benefits (ScienceDirect).
• In retinal ischemia models, Mdivi-1 increased retinal ganglion cell survival and reduced glial activation markers without affecting systemic physiological parameters (APExBIO).

This article extends the mechanistic insights provided in Mdivi-1: Selective DRP1 Inhibitor for Mitochondrial Fission by focusing on translational benchmarks in CIH and OSA models. It also updates quantitative workflow guidance compared to Mdivi-1: Empowering Translational Mitochondrial Dynamics, integrating emerging evidence on gut-mitochondria-apoptosis interplay.

Applications, Limits & Misconceptions

Mdivi-1 is widely applied in apoptosis assays, mitochondrial dynamics research, and neuroprotection models. Its use is validated in both in vitro (e.g., 50 μM in cell lines) and in vivo (e.g., 50 mg/kg in mice, intraperitoneal) workflows (APExBIO). Mdivi-1’s selectivity for DRP1 makes it a preferred tool for dissecting the role of mitochondrial fission in disease. However, some misconceptions persist:

Common Pitfalls or Misconceptions

• Mdivi-1 does not inhibit overall mitochondrial respiration at working concentrations, but high doses may have off-target effects—always validate concentration in new models.
• It is not water-soluble or ethanol-soluble; prepare stocks in DMSO (≥17.65 mg/mL recommended).
• Mdivi-1 does not reduce total DRP1 protein expression; it inhibits its activity.
• The compound’s effects in chronic disease models outside of mitochondrial fission/apoptosis have not been fully established—avoid overgeneralization.
• Long-term storage of Mdivi-1 solutions is not recommended; prepare fresh aliquots for each experiment (APExBIO).

Workflow Integration & Parameters

• Stock Preparation: Dissolve in DMSO to prepare a 10 mM stock (≥17.65 mg/mL solubility in DMSO); store solid at -20°C.
• Cell-based Assays: Use 50 μM final concentration; add directly to culture medium, ensuring DMSO ≤0.1% v/v.
• Animal Models: Typical dose is 50 mg/kg via intraperitoneal injection; administer daily or as per protocol.
• Apoptosis Readouts: Assess annexin V staining, caspase-3 activity, and mitochondrial morphology by microscopy.
• Control Experiments: Include vehicle (DMSO) and positive controls (e.g., CCCP) to verify specificity.

For advanced apoptosis and mitochondrial fission assays, see scenario-driven protocol advice in Mdivi-1 (SKU A4472): Scenario-Driven Solutions for Mitochondrial Dynamics, which this article builds upon by integrating cross-tissue and microbiome evidence from CIH models.

Conclusion & Outlook

Mdivi-1 is a rigorously validated, cell-permeable mitochondrial fission inhibitor that enables targeted modulation of DRP1-mediated apoptosis and mitochondrial dynamics. Evidence from CIH and ischemic models highlights its utility in restoring mitochondrial integrity and reducing cell death. The compound’s specificity, robust solubility in DMSO, and well-defined workflow parameters make it a gold-standard tool for mitochondrial dynamics and neuroprotection research. Looking forward, Mdivi-1 is poised to advance mechanistic studies into the gut-mitochondria-apoptosis axis in chronic disease, as substantiated by recent peer-reviewed and product-based evidence. APExBIO continues to supply high-quality Mdivi-1, empowering translational and fundamental mitochondrial research with best-in-class reagents.